Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 7566

1.

Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals.

Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P, Pupi A, de Leon MJ, Mosconi L.

J Nutr Health Aging. 2015;19(4):413-23. doi: 10.1007/s12603-014-0534-0.

PMID:
25809805
2.

Neuropsychological and Neuroimaging Characteristics of Amnestic Mild Cognitive Impairment Subtypes: A Selective Overview.

Li X, Zhang ZJ.

CNS Neurosci Ther. 2015 Mar 26. doi: 10.1111/cns.12391. [Epub ahead of print]

PMID:
25809732
3.

Cerebrospinal fluid Aβ<sub>42</sub> levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Mar 24. doi: 10.1002/mds.26172. [Epub ahead of print]

PMID:
25808939
4.

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.

Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR Jr, Dickson DW.

Brain. 2015 Mar 23. pii: awv050. [Epub ahead of print]

5.

CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study.

Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, Leyhe T, Bürger K, Taniguchi M, Urakami K, Lista S, Dubois B, Blennow K, Hampel H.

Alzheimers Dement. 2015 Mar 21. pii: S1552-5260(15)00063-1. doi: 10.1016/j.jalz.2014.12.006. [Epub ahead of print]

PMID:
25804998
6.

Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?

Aizenstein HJ, Klunk WE.

Brain. 2015 Apr;138(Pt 4):831-3. doi: 10.1093/brain/awv001. No abstract available.

PMID:
25802317
7.
8.

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Patients with Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis with the C9ORF72 Repeat Expansion.

Kämäläinen A, Herukka SK, Hartikainen P, Helisalmi S, Moilanen V, Knuuttila A, Jansson L, Tienari PJ, Remes AM.

Dement Geriatr Cogn Disord. 2015 Mar 13;39(5-6):287-293. [Epub ahead of print]

PMID:
25791939
9.

Ocular Biomarkers of Alzheimer`s Disease.

Heaton GR, Davis BM, Turner LA, Cordeiro MF.

Cent Nerv Syst Agents Med Chem. 2015 Mar 19. [Epub ahead of print]

PMID:
25788142
10.

The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis.

Scheltens NM, Galindo-Garre F, Pijnenburg YA, van der Vlies AE, Smits LL, Koene T, Teunissen CE, Barkhof F, Wattjes MP, Scheltens P, van der Flier WM.

J Neurol Neurosurg Psychiatry. 2015 Mar 17. pii: jnnp-2014-309582. doi: 10.1136/jnnp-2014-309582. [Epub ahead of print]

PMID:
25783437
11.

Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice.

Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ, Mendenhall MD, Gonzalez-Oregon F, Braun K, Wilcock DM.

J Neuroinflammation. 2015 Dec;12(1):243. doi: 10.1186/s12974-015-0243-6. Epub 2015 Mar 4.

12.

Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.

Körtvélyessy P, Gukasjan A, Sweeny-Reed C, Heinze HJ, Thurner L, Bittner DM.

J Alzheimers Dis. 2015 Mar 16. [Epub ahead of print]

PMID:
25777512
13.

Expert consensus document: Mind the gaps-advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Carman AJ, Ferguson R, Cantu R, Comstock RD, Dacks PA, DeKosky ST, Gandy S, Gilbert J, Gilliland C, Gioia G, Giza C, Greicius M, Hainline B, Hayes RL, Hendrix J, Jordan B, Kovach J, Lane RF, Mannix R, Murray T, Seifert T, Shineman DW, Warren E, Wilde E, Willard H, Fillit HM.

Nat Rev Neurol. 2015 Mar 17. doi: 10.1038/nrneurol.2015.30. [Epub ahead of print]

PMID:
25776822
14.

Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.

Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2015 Mar 16. doi: 10.1001/jamaneurol.2014.4530. [Epub ahead of print]

PMID:
25775167
15.

A test of lens opacity as an indicator of preclinical Alzheimer Disease.

Bei L, Shui YB, Bai F, Nelson SK, Van Stavern GP, Beebe DC.

Exp Eye Res. 2015 Mar 13. pii: S0014-4835(15)00092-5. doi: 10.1016/j.exer.2015.03.010. [Epub ahead of print]

PMID:
25773986
16.

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").

Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S.

Neurotherapeutics. 2015 Mar 14. [Epub ahead of print]

PMID:
25773662
17.

The clinical presentation of chronic traumatic encephalopathy.

Lenihan MW, Jordan BD.

Curr Neurol Neurosci Rep. 2015 May;15(5):541. doi: 10.1007/s11910-015-0541-5.

PMID:
25772999
18.

Memory binding and white matter integrity in familial Alzheimer's disease.

Parra MA, Saarimäki H, Bastin ME, Londoño AC, Pettit L, Lopera F, Della Sala S, Abrahams S.

Brain. 2015 Mar 11. pii: awv048. [Epub ahead of print]

PMID:
25762465
19.

DNA/RNA chimera templates improve the emission intensity and target the accessibility of silver nanocluster-based sensors for human microRNA detection.

Shah P, Choi SW, Kim HJ, Cho SK, Thulstrup PW, Bjerrum MJ, Bhang YJ, Ahn JC, Yang SW.

Analyst. 2015 Mar 11. [Epub ahead of print]

PMID:
25759134
20.

Serum peptides as candidate biomarkers for dementia with Lewy bodies.

Suzuki I, Noguchi M, Arito M, Sato T, Omoteyama K, Maedomari M, Hasegawa H, Suematsu N, Okamoto K, Kato T, Yamaguchi N, Kurokawa MS.

Int J Geriatr Psychiatry. 2015 Mar 6. doi: 10.1002/gps.4274. [Epub ahead of print]

PMID:
25754375
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk